Cycloalkylidene compounds as selective estrogen receptor modulators

1. A compound of formula (I-A):

including pharmaceutically acceptable salts thereof wherein

R 1 is H or F;

R 3 is —(Y) z —R 8 ;

z is 0 or 1;

Y is —CH═CH—;

each of R 6 and R 7 are selected from H or alkyl;

when z is 0, then R 8 is —O(CH 2 ) t CN, —CO 2 H, —(CH 2 ) t CO 2 H, —O(CH 2 ) t CO 2 H, —O(CH 2 ) t OH, —O(CH 2 ) t O(CH 2 ) t OH, or —O(CH 2 ) t C(O)NH 2 ;

when z is 1, then R 8 is —CO 2 H or —CONH 2 ;

each t independently is 1 to 8; and

X is —(CH 2 ) n —, where n is 0, 1, or 2, or O.

2. A compound selected from:

(2E)-3-{4-[Cycloheptylidene(phenyl)methyl]phenyl}prop-2-enoic acid;

(2E)-3-{4-[Cycloheptylidene(phenyl)methyl]phenyl}prop-2-enamide;

2-({4-[Phenyl(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}oxy)ethanol;

2-{[2-({4-[Phenyl (3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}oxy)ethyl]oxy}ethanol;

({4-[(4-Fluorophenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}oxy)acetic acid;

4-({4-[(4-Fluorophenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}oxy)butanoic acid;

({4-[(4-Fluorophenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}oxy)acetonitrile;

2-({4-[(4-Fluorophenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}oxy)ethanol;

(2E)-3-{4-[Phenyl(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}-2-propenoic acid;

4-[Phenyl(3,3,5,5-tetramethylcyclohexylidene)methyl]benzoic acid;

2-{[2-({4-[(4-Fluorophenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}oxy)ethyl]oxy}ethanol;

4-({4-[Phenyl(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}oxy)-1-butanol;

2-({4-[Phenyl(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}oxy)acetamide;

4-({4-[Phenyl(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}oxy)butanoic acid;

({4-[Phenyl(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}oxy)acetic acid;

(2E)-3-{4-[(4-Fluorophenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}-2-propenoic acid;

(2E)-3-{4-[(4-Fluorophenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene)methyl]phenyl}-2-propenoic acid;

(2E)-3-{4-[Phenyl (2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene)methyl]phenyl}-2-propenoic acid;

4-{4-[Phenyl (2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene)methyl]phenyl}butanoic acid;

4-{4-[(4-Fluorophenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene)methyl]phenyl}butanoic acid;

2-({4-[(4-Fluorophenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene)methyl]phenyl}oxy)ethanol;

2-({4-[Phenyl(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene)methyl]phenyl}oxy)ethanol;

2-{[2-({4-[Phenyl(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene)methyl]phenyl}oxy)ethyl]oxy}ethanol;

2-{[2-({4-[(4-Fluorophenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene)methyl]phenyl}oxy)ethyl]oxy}ethanol;

4-[(4-Fluorophenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene)methyl]benzoic acid;

4-[Phenyl(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene)methyl]benzoic acid; and

4-[(4-Fluorophenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]benzoic acid, including pharmaceutically acceptable salts thereof.

3. The compound of claim 1 :

including pharmaceutically acceptable salts thereof.

4. The compound of claim 1 :

including pharmaceutically acceptable salts thereof.

5. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier.

6. A compound according to claim 1 wherein said compound is an active therapeutic substance.

7. A compound according to claim 1 wherein said compound is an modulator.